Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118720 | 0.94 | FFAR1 (0.37) | FFAR1ACACBCA12CA2CA9 | |
| SCHEMBL20118731 | 0.91 | HSD17B1 (0.38) | FFAR1ACACBCA12CA2CA9 | |
| SCHEMBL20118567 | 0.90 | RARB (0.36) | FFAR1ACACBEGLN1EGLN3FFAR4 | |
| SCHEMBL18622100 | 0.84 | FFAR1 (0.33) | FFAR1ACACBCA12CA2CA9 | |
| SCHEMBL19258694 | 0.84 | FFAR1 (0.33) | FFAR1ACACBCA12CA2CA9 | |
| SCHEMBL25573555 | 0.84 | FFAR1 (0.41) | FFAR1FFAR4 | |
| SCHEMBL20118724 | 0.78 | FFAR1 (0.35) | FFAR1ACACB | |
| SCHEMBL17954457 | 0.78 | FFAR1 (0.44) | FFAR1FFAR4 | |
| SCHEMBL20118729 | 0.77 | ACACB (0.44) | FFAR1ACACBCA12CA2CA9 | |
| SCHEMBL19412651 | 0.76 | ACACB (0.39) | FFAR1ACACBCA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667840-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-3529331-B1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-20190330530-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| WO-2018077765-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667840-B2 | Liquid-crystalline medium | FES, BLM, CXCL12 | FFAR1 3447/4885ACACB 2837/4885CA12 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.